Gerrit Klaerner Sells 5,826 Shares of Tricida Inc (NASDAQ:TCDA) Stock

Tricida Inc (NASDAQ:TCDA) insider Gerrit Klaerner sold 5,826 shares of the business’s stock in a transaction dated Monday, July 8th. The shares were sold at an average price of $35.55, for a total transaction of $207,114.30. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

NASDAQ:TCDA opened at $33.23 on Friday. Tricida Inc has a 12 month low of $19.43 and a 12 month high of $42.80. The company has a 50-day moving average price of $36.29. The firm has a market capitalization of $1.66 billion and a price-to-earnings ratio of -7.16. The company has a debt-to-equity ratio of 0.24, a quick ratio of 8.30 and a current ratio of 8.30.

Tricida (NASDAQ:TCDA) last announced its earnings results on Wednesday, May 8th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.80) by ($0.10). Analysts expect that Tricida Inc will post -3.44 earnings per share for the current fiscal year.

Several hedge funds have recently made changes to their positions in the company. Barclays PLC lifted its position in shares of Tricida by 14.4% during the fourth quarter. Barclays PLC now owns 7,176 shares of the company’s stock worth $169,000 after purchasing an additional 906 shares in the last quarter. Quantamental Technologies LLC acquired a new position in shares of Tricida during the first quarter worth approximately $39,000. Marshall Wace North America L.P. lifted its position in shares of Tricida by 99.0% during the first quarter. Marshall Wace North America L.P. now owns 2,591 shares of the company’s stock worth $100,000 after purchasing an additional 1,289 shares in the last quarter. Strs Ohio lifted its position in shares of Tricida by 45.5% during the first quarter. Strs Ohio now owns 4,800 shares of the company’s stock worth $185,000 after purchasing an additional 1,500 shares in the last quarter. Finally, Great West Life Assurance Co. Can acquired a new position in shares of Tricida during the fourth quarter worth approximately $71,000. Institutional investors own 62.89% of the company’s stock.

A number of equities analysts have commented on TCDA shares. Empire boosted their price target on shares of Tricida from $37.00 to $58.00 in a research report on Monday, April 1st. Needham & Company LLC boosted their price target on shares of ViaSat from $78.00 to $100.00 and gave the company a “buy” rating in a research report on Friday, May 24th. Zacks Investment Research lowered shares of Hollysys Automation Technologies from a “hold” rating to a “sell” rating in a research report on Thursday, April 11th. Cowen restated a “buy” rating and issued a $50.00 price target on shares of Tricida in a research report on Tuesday, June 25th. Finally, Goldman Sachs Group started coverage on shares of Tricida in a research report on Wednesday, June 26th. They issued a “buy” rating and a $48.00 price target on the stock. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $47.00.

About Tricida

Tricida, Inc, a pharmaceutical company, focuses on the development and commercialization of its drug candidate, TRC101, a non-absorbed, orally-administered polymer designed as a potential treatment for metabolic acidosis in patients with chronic kidney disease (CKD). It has completed a Phase 3, double-blind, placebo-controlled trial of TRC101 in patients with CKD and metabolic acidosis.

Further Reading: Oversold

Insider Buying and Selling by Quarter for Tricida (NASDAQ:TCDA)

Receive News & Ratings for Tricida Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tricida and related companies with MarketBeat.com's FREE daily email newsletter.